LY96 and metabolic dysfunction-associated steatohepatitis: We conclude that MD2 could be a potential therapeutic target for treatment of NAFLD/NASH, and the small molecule MD2 inhibitor, L6H21, was an effective and selective investigative agent for future mechanistic studies and pre‐clinical drug development.